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ABSTRACT
Objective: To characterize the patterns of autoantibodies to glycolipid complexes in a large cohort
of Guillain-Barré syndrome (GBS) and control samples collected in Bangladesh using a newly
developed microarray technique.
Methods: Twelve commonly studied glycolipids and lipids, plus their 66 possible heteromeric
complexes, totaling 78 antigens, were applied to polyvinylidene fluoride–coated slides using
a microarray printer. Arrays were probed with 266 GBS and 579 control sera (2 mL per serum,
diluted 1/50) and bound immunoglobulin G detected with secondary antibody. Scanned arrays
were subjected to statistical analyses.
Results: Measuring antibodies to single targets was 9% less sensitive than to heteromeric com-
plex targets (49.2% vs 58.3%) without significantly affecting specificity (83.9%–85.0%). The
optimal screening protocol for GBS sera comprised a panel of 10 glycolipids (4 single glycolipids
GM1, GA1, GD1a, GQ1b, and their 6 heteromeric complexes), resulting in an overall assay
sensitivity of 64.3% and specificity of 77.1%. Notable heteromeric targets were GM1:GD1a,
GM1:GQ1b, and GA1:GD1a, in which exclusive binding to the complex was observed.
Conclusions: Rationalizing the screening protocol to capture the enormous diversity of glycolipid
complexes can be achieved by miniaturizing the screening platform to a microarray platform, and
applying simple bioinformatics to determine optimal sensitivity and specificity of the targets. Gly-
colipid complexes are an important category of glycolipid antigens in autoimmune neuropathy
cases that require specific analytical and bioinformatics methods for optimal detection. Neurol
Neuroimmunol Neuroinflamm 2016;3:e284; doi: 10.1212/NXI.0000000000000284
GLOSSARY
AIDP 5 acute inflammatory demyelinating polyneuropathy; AMAN 5 acute motor axonal neuropathy; BSA 5 bovine serum
albumin; FC 5 family controls; GBS 5 Guillain-Barré syndrome; IgG 5 immunoglobulin G; NC 5 neurologic disease controls;
PBS 5 phosphate-buffered saline; ROC 5 receiver operating characteristic.
Autoantibody binding to glycolipids that act as antigens in patients with autoimmune neurop-
athy is heavily influenced by the topographic orientation of the carbohydrate head group within
living peripheral nerve tissue, and also within an immunoassay microenvironment.1 Thus,
clusters of different lipids can interact to form complex molecular shapes capable of acting as
antigens that are not detectable when assaying for individual glycolipid reactivities.2,3 Equally,
some antibody-binding sites on glycolipids may be obscured when the glycolipid is part of
a larger, heteromeric lipid cluster. This new category of glycolipid complex–dependent autoanti-
bodies has recently been described as either complex enhanced or complex attenuated. Anti-
glycolipid antibodies whose binding is unaffected by clustering are referred to as complex
independent.
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Incorporating such findings into the
design of screening assays for antiglycolipid
antibodies adds substantial complexities to
what is already a difficult assay platform to
standardize, even when using single glycoli-
pids as antigens. Thus if one considers 20 dif-
ferent glycolipids as targets, the number of
possible heteromeric complexes in a 1:1 ratio
amounts to 180. If one adds a third lipid to
the cluster, or diversifies the ratios of the
cluster components, combinatorial complex-
ity rises to unmanageable proportions when
using routinely established ELISA-based
immunoassays.
To account for this, and allow us to screen
for antibodies to highly varied glycolipid
complexes in an unbiased way, we have
developed a microanalytical method for as-
saying cohorts of sera against multiple
combinatorial targets that advances our pre-
viously reported methods. In this proof of
principle study, we selected 12 glycolipids
or lipids, plus their 66 possible heteromeric
complexes, totaling 78 antigens. We applied
this assay to identify previously reported
combinatorial targets in a screen of 845
Guillain-Barré syndrome (GBS) and control
samples collected in Dhaka, Bangladesh. We
expected that this geographical setting would
provide a high proportion of axonal GBS
variants and potentially a high chance of cap-
turing antibodies to ganglioside complexes,
as have been previously observed in acute
motor axonal neuropathy (AMAN). Particu-
larly in near-patient settings where early diag-
nosis is useful, simple biomarker testing kits
carrying high sensitivity and specificity that
could be derived from these more complex
datasets are needed. We report the findings
and identify the major clinically useful tar-
gets in this patient group.
METHODS Array fabrication. For full methods, please refer
to the e-Methods at Neurology.org/nn. In brief, array platforms
were produced in-house from polyvinylidene fluoride membrane
adhered to glass microscope slides. Working solutions of single
glycolipids were prepared at 200 mg/mL in methanol, from which
heteromeric complexes were prepared. Glycolipid samples were
stored at 220°C and sonicated prior to printing. Glycolipids
microarray slides were produced using a Sciflexarrayer S3
microarray printer (Scienion; Berlin, Germany). A maximum of
20 slides was printed per run, each containing 16 subarrays per
slide (320 arrays in total). All glycolipid targets were printed in
duplicate on each array and included methanol solvent, which
was printed as a negative control. Upon completion of printing,
arrays were stored at 4°C until required.
Clinical samples. A total of 845 patients with GBS (with asso-
ciated clinical data) and control group sera were collected at Dha-
ka Medical College Hospital, Bangladesh, between 2010 and
2013. GBS cases were enrolled according to National Institute
of Neurological Disorders and Stroke criteria.4 Samples com-
prised 266 patient sera (GBS), 258 family controls (FC), and
321 other neurologic disease controls (NC). Samples were stored
at 270/80°C in the Laboratory Sciences and Services Division.
All patients provided written informed consent; the study was
approved by the ethics committees of the International Centre
for Diarrhoeal Disease Research, Dhaka, Bangladesh, and Dhaka
Medical College, Bangladesh.
Sera screening. Nonspecific serum binding was reduced by
blocking arrays in 2% bovine serum albumin (BSA)/phosphate-
buffered saline (PBS). Each of the 16 subarrays per slide were iso-
lated using a FAST frame including a 16-well incubation
chamber (Maine Manufacturing, Sanford, ME) and 100 mL of
each serum sample, diluted 1:50 in 1% BSA/PBS, was applied per
well for 1 hour at 4°C. Samples were removed from each chamber
and then washed twice in 1% BSA/PBS for 15 minutes at
room temperature. Antibody binding was detected with
100 mL of 2 mg/mL Alexafluor 647 conjugated goat antihuman
immunoglobulin G (IgG) (Jackson ImmunoResearch,West Grove,
PA) per well for 1 hour at 4°C. The arrays were then washed twice
in 1% BSA/PBS for 30 minutes, followed by twice in PBS for
5 minutes and a final 5 minutes wash in distilled water. Each
serum sample was assayed in duplicate and screened twice in 2
independent assays.
Scanning and analysis. Arrays were scanned and quantitated
using a PerkinElmer (Waltham, MA) ScanArray Express instru-
ment. Image analysis was carried out with ProScanArray Express
Easy Quant software. Each target spot was measured for median
fluorescence intensity with local background median pixel inten-
sity subtracted, and the mean value was calculated for each pair of
duplicate spots. Values obtained from repeat runs were averaged
and used in all calculations. Data processing was performed with
Microsoft (Redmond, WA) Excel. Statistical analysis was per-
formed using censReg R, GraphPad prism, MedCalc, and MeV
software. Array data were compared with previously determined
ELISA data for GM1 positivity in 261/266 of the GBS cases
and showed 88.9% agreement (positive or negative).
RESULTS Patient and control sample demographics.
Suspected GBS cases recruited for this study (n 5
299) had the diagnosis of GBS confirmed on sub-
sequent clinical evaluation in 266 patients. A total
of 183 were male (68.8%) and 83 were female
(31.2%). The median/mean age of patients with
GBS was 28/30 years (range 1–75). Electrophysio-
logic examination at one time point after clinical
onset was performed on 192 patients (72.2%) and
classified as follows: acute inflammatory demyelinat-
ing polyneuropathy (AIDP), 58 cases (30.2%);
AMAN, 102 cases (53.1%); unclassified GBS, 32
cases (16.7%). Of the remaining 74 patients who
did not undergo electrophysiologic examination, all
but one patient (who was classified as AIDP) were
categorized as unclassified GBS. Patients reported the
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following preceding symptoms (either in isolation or
in combination with other symptoms): diarrhea, 130
cases (48.9%); respiratory infection, 59 cases
(22.2%); fever, 34 cases (12.8%); chicken pox, 7
cases (2.6%); vaccination, 6 cases (2.3%); other, 21
cases (7.9%). No preceding symptoms were reported
in 32 cases (12.0%). There were 35 deaths (13.2%)
and 58 patients (21.8%) required ventilation at some
point during treatment. For the family and neuro-
logic control demographic and preceding symptom
data, see the e-Methods.
Antiglycolipid antibody screen. The mean intensity val-
ues were calculated from 4 intensity measurements
per target for each serum sample. These 78 targets
are visually represented as a heat map employing
Pearson cluster coefficient and displayed as 3 groups:
GBS (n 5 266), FC (n 5 258), and NC (n 5 321),
with antibody binding intensity portrayed in a rain-
bow scale, red being high binding and blue being low
binding (figure 1A). As expected for a GBS popula-
tion in which multiple targets are known to be pres-
ent, no single antigen binding pattern was dominant
throughout the cohort examined. Instead, 30 targets
were found with significantly increased (p , 0.05)
binding intensities in GBS as compared indepen-
dently with both FC and NC groups. These data
on 30 significant targets are also displayed solely for
the GBS group for simplicity (figure 1B). Twenty-
eight of the targets in the GBS group were
heteromeric complexes and 2 (GA1 and GM1)
were single glycolipids. While these 30 targets are
highly significantly different between disease and
control groups and may be clinically useful when
multiple tests are performed, screening for one
antigen or antigen complex cannot be used to
determine a measure of clinical usefulness by
receiver operating characteristic (ROC) analysis, due
to the low sensitivity of individual targets. Indeed, as
expected, when subjected to ROC analysis, no targets
reached area under the curve $0.75 (the minimal
level considered to be the gold standard for
a clinically useful biomarker5) when compared with
combined (family and neurologic) control groups.
Certain targets (containing SGPG, cholesterol,
and GA1) returned higher than average signals across
both disease and control groups, indicating that nor-
mal ranges need to be determined for each antigen.
Optimized positivity threshold values were calculated
for each target antigen, defined as the 95th percentile
of the combined controls. All intensity values were
converted to binary data (positive/negative), deter-
mined by the optimal threshold calculated for each
target, and all subsequent data are expressed in terms
of sensitivity and specificity. When considering all 78
targets, a sensitivity of 82.7% and a specificity of
37.1% was achieved, indicating that 62.9% of the
combined control samples had antibody binding
intensity greater than the threshold for one or more
of the 78 targets, despite only 5% of controls being
positive for any one individual antigen target. In order
to increase the specificity of the assay, we established
a refined panel of target antigens.
Anti-GM1, -GA1, -GD1a, and -GQ1b antibodies. Focus-
ing on 4 glycolipids that are already recognized to be
targets in GBS and were prominent antigens in this
screen, several common cluster patterns comprising
GM1, GA1, GD1a, and GQ1b alone or in complex
could be identified (figure 2A). The largest group of
sera contained anti-GM1 antibodies (n 5 92;
sensitivity 5 34.6%). Many of these also bound
to GM1 when in heteromeric complex; however,
in some cases, binding to GM1 was inhibited
when in heteromeric complex with another
glycolipid. Considering the samples in which
heteromeric complexes enhanced anti-GM1
antibody binding, GM1:GD1a and GM1:GQ1b
complexes were prominent pairings, many of these
samples containing completely complex-dependent
antibodies (i.e., without the complex, the antibody
would not be identifiable as there was no reactivity
above threshold for each individual ganglioside).
Thus of the 98 (36.8%) GBS sera that bound
GM1:GD1a complex, 25 were completely
complex dependent. Of the 98 (36.8%) GBS sera
that bound GM1:GQ1b complex, 27 were
completely complex dependent (figure 2, E–F).
Antibody binding events were infrequent in the
AMAN population for GA1 (37/102; 36.3%) and
GD1a (14/102; 13.7%) when considered as single
antigens, compared with other GBS populations in
which anti-GD1a-positive AMAN cases are more
prominent.6 However, the GA1:GD1a complex was
a significant target in 36 (35.3%) AMAN samples, of
which 10 were completely complex dependent (figure
2, B–D). Similarly, GM1:GD1a was a significant tar-
get in 57 (55.9%) AMAN samples, of which 14 were
complex dependent. In this clinical population, both
GA1 and GM1 therefore appear to enhance anti-
GD1a antibody detection when the 2 glycolipids
are in complex.
Complex enhancement and complex inhibition. In order
to illustrate the enhancing and inhibiting effect of
complexes, exemplary data are presented for GA1:
GD1a (figure 2, B–D) and GM1:GQ1b (figure 2,
E–G). Heterogeneous patterns are found, as ex-
pected. Thus there are 2 populations of anti-
GA1:GD1a antibodies in GBS sera: (1) those in
which binding intensities to GA1 or GD1a are
attenuated by GA1:GD1a complex and (2) those
in which binding is greatly enhanced by the
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Figure 1 Heat map of antibody binding patterns to glycolipid targets in Guillain-Barré syndrome (GBS) cases
and controls
(A) Patient (GBS) and control sera (family controls [FC] and neurologic disease controls [NC]) were screened against a panel
of 78 single and heteromeric glycolipid targets on glycolipid microarray. Mean fluorescent intensity values were calculated
and graphically presented as a heat map. The rainbow scale indicates the intensity of the antibody binding, in which blue is
weak and red is strong antibody binding. Pearson hierarchical clustering was employed to group samples with similar anti-
gen binding patterns. (B) Heat map presentation of GBS samples for the 30 glycolipid targets identified as having signifi-
cantly different binding intensities between GBS and FC or NC groups (p , 0.05).
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Figure 2 Subanalysis of 10 major antiglycolipid antibody targets in Guillain-Barré syndrome (GBS) cases
(A) Heat map presentation of patient (GBS) and control sera (family controls [FC] and neurologic disease controls [NC]) reactivity with GM1, GD1a, GQ1b, and
GA1 as single antigens and their 6 possible heteromeric complexes. When selecting this small panel of 10 targets as serum biomarkers of GBS in this clinical
cohort, the combined sensitivity is 64.3% and the specificity is 77.1%. (B) Dot plot presentation of GBS (n5266) antibody binding intensities for single GA1
and GD1a and their heteromeric complex, GA1:GD1a. (C) Heat map presentation of patient binding intensities. Each row represents a single patient, with
binding intensity to each target represented using the rainbow scale. (D) Line graph compares the binding intensity for complex GA1:GD1a with the sum of
the single antigens (GA1 and GD1a). Green lines indicates complex enhancement, while red lines represent complex attenuation. (E) Dot plot presentation of
GBS (n 5 266) antibody binding intensities for single GM1 and GQ1b, and their heteromeric complex, GM1:GQ1b. (F) Heat map presentation of patient
binding intensities. Each row represents a single patient, with binding to each target represented using the rainbow scale. (G) Line graph compares the
binding intensity for complex GM1:GQ1b with the sum of the single antigens (GM1 and GQ1b). Green lines indicates complex enhancement, while red lines
represent complex attenuation.
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complex, most usually in a completely complex-
dependent fashion (i.e., no binding is present to
either partner alone; figure 2D, green lines).
Similarly, when considering GM1 and GQ1b,
while some anti-GM1 and anti-GQ1b sera have
attenuated binding intensities when in GM1:
GQ1b complex, there is a significantly large
group of sera in which major enhancement
occurs in the presence of the complex (figure 2G,
green lines).
The added value and limitations of screening for
heteromeric complexes. To assess the overall impact
of including glycolipid heteromeric complexes in
the screening platform, we compared the number of
GBS samples classified as positive (i.e., returning an
intensity value .95th percentile of the combined
controls) for single glycolipids and heteromeric com-
plexes for the 10 frequently observed reactivities (fig-
ure 2A). A total of 131 of 266 GBS samples and 87 of
579 combined controls were positive for one or more
single targets (sensitivity 49.2%, specificity 85.0%),
whereas 155/266 GBS samples and 95/579 com-
bined controls were positive for one or more hetero-
meric complexes (sensitivity 58.3%, specificity
83.6%). Therefore, by screening for heteromeric
complexes, a gain of 9.1% in sensitivity (p 5
0.0021) is achieved without a significant loss in spec-
ificity (1.4%; p 5 0.445). Screening of GBS sera,
irrespective of the clinical variant (AMAN, AIDP,
or unclassified), against this discrete panel of 10 gly-
colipids (4 single and 6 complexes) resulted in an
overall assay sensitivity of 64.3% and specificity of
77.1%.
However, when examining a larger panel of tar-
gets, a gain in sensitivity is frequently offset by an
equivalent or greater loss in specificity (figure 3A).
For example, when examining the 30 targets with
significantly different fluorescent intensity values (fig-
ure 1B), a gain of 30.4% in sensitivity (from 41.0%
to 71.4%) is offset by a loss of 29% specificity (from
91.2% to 62.2%) when comparing single and com-
plex positivity frequency. Similarly, when considering
all 78 targets printed on the glycolipid arrays, there is
a 14.7% gain in sensitivity (from 65.0% to 79.7%),
while specificity drops 24.3% (from 65.8% to
41.5%) for single and complexes, respectively. These
data show that when examining the data in its total-
ity, the disease specificity of a very broad unbiased
screen is expectedly poor, owing to the large number
of controls whose sera contain at least one species of
antiglycolipid antibody above the normal range
(.95th percentile).
Antiglycolipid antibodies associated with clinical
variants. Correlation between antiglycolipid anti-
body profiles and clinical features are presented in
table and as e-Results. Having determined a panel
of 10 glycolipid reactivities optimized for sensitivity
and specificity for all patients with GBS irrespective
of the clinical variant, next we sought to determine
whether the presence of specific antibody reactiv-
ities would segregate with a clinical variant, or could
be used to predict the clinical phenotype or out-
come (see e-Results). Patients who had unclassified
Figure 3 Sensitivity and specificity of microarray analysis in relation to target
number
(A) Comparison of overall assay accuracy (both sensitivity and specificity) when screening
against an increasing number of target antigens. Assay specificity declines as the numbers
of target antigens increases. Improved assay performance is achieved when a small panel of
10 targets is selected. (B) Dot plot compares the maximum binding intensity signal for each
patient or control when comparing single and heteromeric complexes. GBS patient median
arbitrary binding intensity for single targets (747.3 FIU) is significantly less than for hetero-
meric complex targets (3589.9 FIU; p , 0.0001), indicating that heteromeric complexes
return higher signals than single antigens.
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GBS variants (n 5 105) were excluded from this
analysis. Six targets were identified as being signif-
icant in the AIDP population when compared with
the AMAN clinical variant. These included SGPG
alone, as well as 2 complexes containing SGPG
(SGPG:GQ1b and SGPG:Chol). In addition, 2
heteromeric complexes containing LM1 (LM1:Sul-
phatide and LM1:Chol) and CTH:Chol were sig-
nificantly associated with AIDP (p , 0.05). While
significant, each of these targets was present at low
frequencies within the patient samples, and thus
individually they had low diagnostic sensitivity
(ranging from 10.5% to 14.0%), but with a high
specificity both for combined controls (95.0%) and
patients with AMAN (ranging from 96.0% to
98.0%, depending upon the target). When com-
bined as a diagnostic panel of 6 antigen targets for
AIDP, a sensitivity of 33.9% and a specificity of
87.3% and 83.4% (for AMAN and controls, respec-
tively) was reached.
Table Glycolipid reactivities associated with acute inflammatory demyelinating polyneuropathy (AIDP)
andacute motor axonal neuropathy (AMAN) clinical variants
AIDP (n 5 59) AMAN (n 5 102)
Guillain-Barré syndrome variant biomarker SGPG GM1 single 1 All GM1 complexes
SGPG:GQ1b GA1 single 1 All GA1 complexes (excl. GA1:GQ1b)
SGPG:Chol GD1b:GD1a
LM1:Sulph GD1b:PS
LM1:Chol GD1b:Chol
CTH:Chol GD1b:Sulph
Ocular deficits GQ1b:GD1b N/A
GQ1b:SGPG
GQ1b:CTH
GQ1b:Chol
GQ1b:GalC
LM1:CTH
Bulbar palsy N/A GQ1b:PS
Facial palsy N/A GA1:GD1a
Figure 4 Heat map of antibody binding patterns in axonal vs demyelinating Guillain-Barré syndrome (GBS)
cases
(A) Heat map presentation of the 26 glycolipid targets significant for the acute motor axonal neuropathy variant of GBS
compared with the demyelinating (acute inflammatory demyelinating polyneuropathy) clinical subtype. (B) Refining the
screening targets to a panel of 3 heteromeric complexes (GM1:GQ1b, GM1:phosphatidylserine, and GA1:GD1a) results
in a sensitivity of 78.4% and a specificity of 87.7% (for combined controls).
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Twenty-six targets were identified as being sig-
nificant (p , 0.05) in AMAN when compared with
the AIDP population (figure 4A). These include
GM1 alone plus GM1 in complex with all tested
lipids (GM1:GA1, GM1:GD1a, GM1:GD1b,
GM1:GQ1b, GM1:SGPG, GM1:LM1, GM1:
CTH, GM1:PS, GM1:Chol, GM1:Sulphatide,
GM1:GalC), GA1 alone plus GA1 in complex with
all tested lipids, with the exception of GA1:GQ1b
(GA1:GD1a, GA1:GD1b, GA1:SGPG, GA1:LM1,
GA1:CTH, GA1:PS, GA1:Chol, GA1:Sulphatide,
GA1:GalC), GD1b:GD1a, GD1b:PS, GD1b:Chol,
and GD1b:Sulphatide. Of these, GM1:GD1a had
the highest sensitivity (55.9%) and a high specific-
ity for both combined controls (95.0%) and pa-
tients with AIDP (84.8%). When combined as
a diagnostic panel of 26 antigen targets for AMAN,
a sensitivity of 86.3% and a specificity of 64.4%
and 45.8% (for combined controls and AIDP,
respectively) was reached. As previously demon-
strated, the specificity was reduced with increasing
antigen targets; therefore, we sought to refine the
number of antigen targets in order to optimize sen-
sitivity and specificity. When selecting only 3 anti-
gen targets (GM1:GQ1b, GM1:PS, and GA1:
GD1a), a sensitivity of 78.4% and specificity of
87.7% and 61.0% (for combined control and
AIDP, respectively) was achieved (figure 4B).
DISCUSSION This study applies technical develop-
ments in antiglycolipid antibody assay miniaturization
to address the practical complexities of large-scale
biomarker screening of clinical cohorts. By adapting
the microarray printer to accommodate glycolipids,
we were able to print arrays in a high throughput
manner. One maximum capacity assay is capable of
printing 320 individual arrays, on a total of 20
slides. Conducting an equivalent screen on this
sample size and antigen repertoire in a conventional
ELISA study would require 640 ELISA plates (96-
well). Miniaturization of the glycolipid assay allows
us to use 100-fold smaller volumes of patient serum,
thus the total serum use by microarray is 2 mL to
probe against 78 target antigens with duplicate
measurement, compared with 200 mL of serum for
a comparable study performed on ELISA. In addition,
the use of fluorescently conjugated antibodies allows
for multiplex screening, whereby IgG and
immunoglobulin M can be detected simultaneously
on each assay platform, a benefit not routinely
available in ELISA readers.
In this study, a single electrophysiologic assess-
ment was performed on 192 of the 266 patients
in the GBS cohort. Of these patients, 53.1% of pa-
tients were classified as having an axonal variant of
GBS, 30.2% of patients with AIDP, while the
clinical variant of the remaining 16.7% of patients
was unclassified. These diagnostic categorization
frequencies are in line with a previously reported
GBS cohort from Bangladesh.7 As found here, this
previous report also identified a low incidence of
patient serum containing anti-GD1a antibodies
(14%), which was surprising given the high fre-
quency of axonal GBS, in comparison with studies
from elsewhere.6,8–10 However, probing Bangladesh
sera against heteromeric complexes proved
advantageous as it revealed populations of complex-
dependent GA1:GD1a and GM1:GD1a antibodies,
which were distinct from antibodies binding GD1a as
a single antigen. Similarly, GM1:GQ1b complex-
dependent antibody binding was identified as a dis-
tinct population in 11.9% of AMAN samples, when
compared to GM1 and GQ1b alone. Using a refined
panel of only 3 antiglycolipid targets, a high sensitivity
and specificity was achieved for patients with AMAN
in this cohort.
In addition to screening GBS patient samples, 579
combined control sera were examined. This screen
identified variations in the baseline levels of antigan-
glioside antibodies reactivities for each of the targets.
When performing conventional ELISA, the current
gold standard method for antiganglioside antibody
detection, a universal optical density threshold of pos-
itivity across all glycolipids, is widely used. In this
geographically restricted study, we can see that in
order to optimize both sensitivity and specificity of
the assay, individual threshold must be calculated,
in order to determine the normal range of these nat-
urally occurring and GBS-independent anticarbohy-
drate antibodies.
In this study, we present data that identify the
presence of both single and heteromeric glycolipid
complex binding antibodies in this large GBS cohort.
Initial biomarker screening employed a panel of 78
targets; however, the selective inclusion of a very lim-
ited panel of targets enabled optimization of both sen-
sitivity and specificity due to significant target
redundancy resulting from the presence of polyclonal
antibodies or cross-reactivity of specific antibody
species. When considering the overwhelming com-
plexities of identifying diagnostically important glyco-
lipid complexes by ELISA screening, the necessities
of miniaturization are clearly evident for the initial
analysis in order to find the markers that are most
informative.
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